Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator.
10.1016/j.apsb.2022.12.012
- Author:
Jingwen DONG
1
;
Chenfei ZHU
1
;
Ying HUANG
1
;
Quanhao LI
1
;
Jing LI
1
;
Zheng WANG
1
;
Yixin WANG
1
;
Zhanwei ZHOU
1
;
Minjie SUN
1
Author Information
1. NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
- Publication Type:Journal Article
- Keywords:
AMD3100;
CXCR4/CXCL12;
Deep penetration;
Fibrosis;
Immune exclusion;
Immunotherapy;
Metastasis;
PAI-1
- From:
Acta Pharmaceutica Sinica B
2023;13(7):3106-3120
- CountryChina
- Language:English
-
Abstract:
Fibrosis is one of the key factors that lead to the immune exclusion of solid tumors. Although degradation of fiber is a promising strategy, its application was still bottlenecked by the side effects of causing metastasis, resulting in the failure of immunotherapy. Here, we developed an antimetastatic polymer (HPA) for the delivery of chemo-drug and antifibrotic siPAI-1 to form the nano-permeator. Nano-permeator shrank after protonation and deeply penetrated into the tumor core to down-regulate the expression of PAI-1 for antifibrosis, and further promoted the sustained infiltration and activation of T cells for killing tumor cells. Moreover, metastasis after fiber elimination was prevented by multivalent CXCR4 antagonistic HPA to reduce the attraction of CXCL12 secreted by distant organs. The administration of stroma-alleviated immunotherapy increased the infiltration of CD8+ T cells to 52.5% in tumor tissues, inhibiting nearly 90% metastasis by HPA in distant organs. The nano-permeator reveals the mechanism and correlation between antifibrosis and antimetastasis and was believed to be the optimizing immunotherapy for solid fibrotic tumors.
